CVS Health Magnesium Citrate Oral Solution Recalled Nationwide Due to Acetobacter Nitrogenifigens Contamination
CVS Pharmacy, Inc. faces a nationwide Class II recall of 13,344 bottles of its Magnesium Citrate Oral Solution, initiated by Pharma Nobis LLC, due to contamination with Acetobacter nitrogenifigens bacteria. This event underscores critical quality control vulnerabilities in non-sterile drug manufacturing, impacting supply chain integrity and consumer trust for CVS Pharmacy, Inc. and its partners.
FDA Class II Recall: Microbial Contamination of CVS Health Magnesium Citrate Oral Solution
On December 21, 2023, Pharma Nobis LLC initiated a voluntary, firm-initiated Class II recall of 13,344 bottles of CVS Health Magnesium Citrate Saline Laxative Oral Solution DYE FREE Grape Flavor, distributed nationwide by CVS Pharmacy, Inc. The recall, assigned reference number D-0229-2024, was officially reported on January 24, 2024, and remains ongoing. The critical issue identified is microbial contamination, specifically the presence of *Acetobacter nitrogenifigens* bacteria, in this non-sterile oral product. The affected lot is A80763, with an expiration date of November 2025. This incident highlights significant quality control lapses within the manufacturing process for a widely available over-the-counter (OTC) medication. For procurement directors and supply chain VPs, this means an immediate disruption to the availability of this specific Magnesium Citrate product across CVS Pharmacy, Inc.'s extensive retail network. The presence of *Acetobacter nitrogenifigens* in an oral solution, while a Class II recall suggests the probability of serious adverse health consequences is remote, still poses a risk, particularly for immunocompromised individuals. This necessitates a rapid assessment of inventory, potential stock-outs, and the need for alternative sourcing strategies to maintain product availability and consumer confidence in the Magnesium Citrate category. Regulatory affairs heads must immediately review their product quality assurance frameworks, especially for non-sterile liquid formulations, to prevent similar contamination events.
Supply Chain Exposure and Distribution Impact for CVS Pharmacy, Inc.
The recalled CVS Health Magnesium Citrate Saline Laxative Oral Solution, identified by NDC 51316-881-10, was distributed nationwide across the United States. CVS Pharmacy, Inc., as the named distributor and brand owner, bears significant responsibility for the quality and safety of products sold under its brand. While the recalling firm is Pharma Nobis LLC, located at 7400 Alumax Rd, Texarkana, TX 75501-0282, the direct impact of this recall reverberates through CVS Pharmacy, Inc.'s extensive retail footprint. For supply chain VPs, this event mandates an urgent review of all Magnesium Citrate product lines and potentially other non-sterile oral solutions supplied by Pharma Nobis LLC or similar contract manufacturers. The nationwide distribution pattern means that the logistical challenges of retrieving 13,344 contaminated bottles are substantial, incurring costs related to reverse logistics, destruction, and potential lost sales. Business development executives should consider the potential for brand erosion and the need for proactive communication strategies to reassure consumers about the safety of other CVS Health branded products. This incident also underscores the critical importance of robust supplier qualification programs, particularly for generic OTC medications where cost pressures might inadvertently lead to compromises in quality oversight. Companies must ensure that their contract manufacturing organizations (CMOs) adhere to the highest standards of Good Manufacturing Practices (GMP) to prevent microbial contamination, which can have far-reaching commercial and reputational consequences.
Regulatory Compliance Imperatives and Quality System Scrutiny
The voluntary, firm-initiated nature of this recall, following an initial notification via E-Mail, indicates Pharma Nobis LLC's acknowledgment of the microbial contamination issue. However, the presence of *Acetobacter nitrogenifigens* bacteria in a non-sterile oral solution points to fundamental deficiencies in environmental monitoring, sanitation, or raw material control within the manufacturing process. For regulatory affairs heads, this incident serves as a critical reminder of the FDA's stringent expectations for microbial control in drug products, even those classified as non-sterile. Companies must implement comprehensive quality management systems that include rigorous microbial testing at various stages of production, robust cleaning and sanitization protocols, and effective investigation into any out-of-specification results. The FDA's ongoing classification of this recall as 'Ongoing' signifies continued regulatory oversight and the expectation for Pharma Nobis LLC and CVS Pharmacy, Inc. to conduct a thorough root cause analysis and implement effective corrective and preventive actions (CAPA). Failure to adequately address the underlying causes of contamination could lead to further regulatory actions, including potential Warning Letters, import alerts (if applicable to foreign facilities), or even consent decrees, severely impacting market access and operational continuity. This event necessitates a proactive review of all quality agreements with CMOs to ensure clear accountability and adherence to regulatory standards.
Strategic Procurement Considerations for Magnesium Citrate and OTC Drugs
While the provided intelligence does not name specific alternative suppliers for Magnesium Citrate, this recall underscores the critical need for procurement directors to diversify their sourcing strategies for essential over-the-counter (OTC) ingredients and finished products. Relying on a single supplier or a limited pool of manufacturers, especially for high-volume, generic products like Magnesium Citrate, exposes businesses to significant supply chain vulnerabilities when quality issues arise. Procurement teams should immediately initiate a review of their supplier matrices for Magnesium Citrate and other similar non-sterile oral solutions, identifying and qualifying secondary or tertiary suppliers. This qualification process must go beyond price, focusing heavily on a supplier's regulatory compliance history, quality management system robustness, and proven track record in microbial control. Geographic diversity in sourcing can also mitigate regional supply disruptions or regulatory enforcement trends. Business development executives should understand that a robust, diversified supply chain is not merely a cost center but a strategic asset that protects brand reputation and ensures market continuity. The time and resources invested in qualifying new suppliers, though substantial, are a necessary safeguard against the commercial fallout from contamination events like the one impacting CVS Health Magnesium Citrate products.
Remediation Timeline and Future Regulatory Outlook
The recall of CVS Health Magnesium Citrate Saline Laxative Oral Solution remains 'Ongoing' as of the latest report date, January 24, 2024. This status indicates that Pharma Nobis LLC and CVS Pharmacy, Inc. are actively engaged in the recall process, which includes notifying affected customers, retrieving product from the market, and investigating the root cause of the *Acetobacter nitrogenifigens* contamination. For regulatory affairs and business development executives, the immediate future involves a comprehensive remediation effort. Pharma Nobis LLC will be expected to submit a detailed corrective and preventive action (CAPA) plan to the FDA, outlining how they will address the contamination issue, prevent recurrence, and ensure future product quality. This typically involves re-evaluating manufacturing processes, environmental controls, raw material testing, and personnel training. The FDA will closely monitor these actions, potentially through follow-up inspections, to verify compliance. Failure to implement effective CAPA could escalate regulatory scrutiny, impacting the ability of Pharma Nobis LLC to manufacture and supply products and potentially affecting CVS Pharmacy, Inc.'s ability to source from them. This event serves as a clear signal that the FDA maintains a vigilant stance on microbial contamination in non-sterile drugs, and companies must prioritize robust quality systems to avoid significant commercial and reputational damage.